Internationale Zeitschrift für Entzündung, Krebs und integrative Therapie

Abstrakt

Final Efficacy Results of a Randomized Phase II Study of Recombinant Interleukin-21 Compared to Decarbonize in Patients with Recurrent or Metastatic Melanoma

Dr.Teresa M. Petrella

Interleukin-21(IL-21) is a T-cell derived cytokine with antitumour activity
dependent on NK cells or CD8+ T cells. A previous phase II study demonstrated
an overall response rate (ORR) of 22.5% in previously untreated patients with
metastatic melanoma. We conducted a multi-centre randomized phase II study in
metastatic melanoma patients to evaluate the efficacy, toxicity, immunogenicity
and biomarkers associated with response to IL-21 versus dacarbazine (DTIC).